c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.
about
Role of mesenchymal cells in the natural history of ovarian cancer: a reviewOvarian cancer stem cells: Can targeted therapy lead to improved progression-free survival?Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approachRegulation of ovarian cancer stem cells or tumor-initiating cellsThe role of tumor microenvironment in therapeutic resistanceβ-Catenin-regulated ALDH1A1 is a target in ovarian cancer spheroidsC-kit induces epithelial-mesenchymal transition and contributes to salivary adenoid cystic cancer progressionTissue transglutaminase regulates β-catenin signaling through a c-Src-dependent mechanism.Metformin against cancer stem cells through the modulation of energy metabolism: special considerations on ovarian cancer.Role of EZH2 in cancer stem cells: from biological insight to a therapeutic target.Possible prognostic and therapeutic significance of c-Kit expression, mast cell count and microvessel density in renal cell carcinoma.A mathematical model of bimodal epigenetic control of miR-193a in ovarian cancer stem cellsOvarian cancer stem cells: are they real and why are they important?Downregulation of miR-200a induces EMT phenotypes and CSC-like signatures through targeting the β-catenin pathway in hepatic oval cells.β-catenin enhances odontoblastic differentiation of dental pulp cells through activation of Runx2.Galectin-3 augments tumor initiating property and tumorigenicity of lung cancer through interaction with β-catenin.Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical updateMolecular staging of gynecological cancer: What is the future?Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells.MiR-1207 overexpression promotes cancer stem cell-like traits in ovarian cancer by activating the Wnt/β-catenin signaling pathway.Mechanisms of chemoresistance in cancer stem cells.Role of the microenvironment in ovarian cancer stem cell maintenance.Stemness and chemoresistance in epithelial ovarian carcinoma cells under shear stress.CD117 expression in operable oesophageal squamous cell carcinomas predicts worse clinical outcome.Involvement of NRF2 Signaling in Doxorubicin Resistance of Cancer Stem Cell-Enriched Colonospheres.A novel p70 S6 kinase-microRNA biogenesis axis mediates multicellular spheroid formation in ovarian cancer progression.Targeting XBP1-mediated β-catenin expression associated with bladder cancer with newly synthetic Oridonin analogues.Dynamic Interactions Between Cancer Stem Cells And Their Stromal Partners.Catching moving targets: cancer stem cell hierarchies, therapy-resistance & considerations for clinical intervention.Reduced expression of FILIP1L, a novel WNT pathway inhibitor, is associated with poor survival, progression and chemoresistance in ovarian cancer.Targeting estrogen-related receptor alpha inhibits epithelial-to-mesenchymal transition and stem cell properties of ovarian cancer cellsOvarian cancer stem cells: still an elusive entity?STROBE-compliant integrin through focal adhesion involve in cancer stem cell and multidrug resistance of ovarian cancerPharmacological modulation of beta-catenin and its applications in cancer therapyInvestigating molecular profiles of ovarian cancer: an update on cancer stem cells.The molecular mechanisms underlying the therapeutic resistance of cancer stem cells.Silencing dishevelled-1 sensitizes paclitaxel-resistant human ovarian cancer cells via AKT/GSK-3β/β-catenin signalling.Mir-152 inhibits cell proliferation and colony formation of CD133(+) liver cancer stem cells by targeting KIT.Cancer stem-like cells from head and neck cancers are chemosensitized by the Wnt antagonist, sFRP4, by inducing apoptosis, decreasing stemness, drug resistance and epithelial to mesenchymal transition.Repression of c-Kit by p53 is mediated by miR-34 and is associated with reduced chemoresistance, migration and stemness.
P2860
Q26823555-5A1C5CBC-79B0-4186-823B-F914E12576B2Q26826899-D1203BE4-3322-48AA-8404-4CD9CD96D0FEQ26849477-8781F083-B3D1-4426-88E2-C83EA6A2189EQ26853096-CFE538A5-5DD0-4E41-8378-EEA5530B4360Q28069049-EDE85ACB-8CA7-4D44-AA85-9502825A7489Q30370274-96BC2B22-EC4D-42AD-B9A9-BC7E29B567A8Q33688902-79ED816A-53AE-4BA1-8A1C-C56460F6A0F7Q33730021-E4168166-5A54-47D9-9A91-429813CFCBF7Q33890763-863967CF-687E-4C4C-AE01-23816DFEFBB1Q33914216-FCB3A5F9-9B97-4462-B4FA-528D57296102Q34072594-C03A8B50-0DD5-4D03-A627-47D4260773EBQ34784456-52B6D1B3-CEAE-47E1-8BBC-2C0437B749C0Q35047699-A4AE55DA-0FE4-45FF-AB47-34BE373E8C9BQ35048411-7DE02156-421E-483D-B86E-2BD3E69ACD72Q35092927-261293D8-EEEB-44E7-8068-54435546A4D7Q35741579-4B433D43-80F1-45EF-8EA4-0321645663BEQ35904534-9F224BAF-6AD1-49E6-B0C6-15AEE7043576Q35940829-6501BBCE-F0EC-4FD0-A36F-2529E53A07E0Q36031339-55F791CE-3ACB-4B76-9021-B2D7A23DD4A4Q36557159-2F33421A-06DC-4DB1-9550-6AF7DA6B3CB0Q36591484-BF874F58-8AD5-421D-98C9-B3737B5ECAA1Q36665179-E4640DC6-EF69-4AB1-9B97-2F31A335317CQ36953366-9FFC15AD-53ED-48B9-AF39-BC9071301A77Q37016233-E681D198-49AC-42BC-B051-EA798F8D377DQ37235244-031F10DD-4710-41BF-B186-02E01212791DQ37437403-DB373A6F-EC10-4015-B3D9-4F4F8D64A83EQ37636708-934F915B-6B1F-40F6-94CB-DEA0F238915AQ37641700-62BB16F7-9C1A-4668-BAD0-E136ADC3EF77Q37661508-EF772ADB-83E3-4C66-B19C-B9F9C58FF140Q37684607-34003CF4-349F-4DC9-B757-A4D34E304372Q37696020-DE4C686B-D583-4BCC-9B3C-C7A95A7DD893Q37713683-A086AFF5-4519-44FE-B38B-51DF9B78D5C3Q37727225-AD4B736A-31A2-4EE6-B3F2-2FCAF12C2FDCQ38089341-B0771335-5910-4952-A9D9-4F5F86CF5911Q38203882-F3213A9D-700E-4CDA-BDEE-13C440989B11Q38287226-6C7AC508-8B5E-4D49-B88A-2BF52F61412FQ38913984-EBC23004-5297-41B0-AFD0-95FB1460D1D5Q38948202-CCB8EDE1-0F53-40FA-9E7A-DC40DFCD8901Q38967885-C2CAF5BD-9991-4FCF-9605-47EA5BCC4D79Q39099572-67120473-A90B-44F0-BB06-F103AA92B1C6
P2860
c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
c-Kit mediates chemoresistance ...... binding cassette G2 signaling.
@en
c-Kit mediates chemoresistance ...... binding cassette G2 signaling.
@nl
type
label
c-Kit mediates chemoresistance ...... binding cassette G2 signaling.
@en
c-Kit mediates chemoresistance ...... binding cassette G2 signaling.
@nl
prefLabel
c-Kit mediates chemoresistance ...... binding cassette G2 signaling.
@en
c-Kit mediates chemoresistance ...... binding cassette G2 signaling.
@nl
P2093
P2860
P356
P1433
P1476
c-Kit mediates chemoresistance ...... -binding cassette G2 signaling
@en
P2093
P2860
P2888
P304
P356
10.1038/ONC.2012.290
P407
P50
P577
2012-07-16T00:00:00Z